Spots Global Cancer Trial Database for Phase I Study of BI 831266 in Patients With Advanced Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of BI 831266 in Patients With Advanced Solid Tumours
Official Title: An Open-label Phase I Single Dose Escalation Trial of Two Dosing Schedules of BI 831266 Administered Intravenously Over 24 h Continuously in Patients With Advanced Solid Tumours
Study ID: NCT00756223
Conditions
Study Description
Brief Summary: The main objective of this trial is to provide safety data in terms of drug-related adverse events for the recommendation of the dose for further trials in the development of BI 831266. Secondary objectives are the collection of antitumour efficacy data and the determination of the pharmacokinetic and pharmacodynamic profile of BI 831266.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1257.1.4303 Boehringer Ingelheim Investigational Site, Linz, , Austria
1257.1.4302 Boehringer Ingelheim Investigational Site, Salzburg, , Austria
1257.1.4301 Boehringer Ingelheim Investigational Site, Wien, , Austria
Contact Details
Name: Boehringer Ingelheim
Affiliation: Boehringer Ingelheim
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
